Sign In
Buy OTLK
$0.98
-0.0634 (-6.10%)
At Close: Jul 31, 2026
US FDA declines to approve Outlook Therapeutics' eye disease drug
06:35am, Wednesday, 30'th Aug 2023
Outlook Therapeutics said on Wednesday the U.S. Food and Drug Administration declined to approve its experimental eye disease drug, in part due to manufacturing issues observed during pre-approval ins
Outlook Therapeutics' stock tumbles 71% premarket after FDA rejects treatment for wet AMD
06:29am, Wednesday, 30'th Aug 2023
Outlook Therapeutics Inc.'s stock OTLK, +10.16% tumbled 71% in premarket trade Wednesday, after the company said the U.S. Food and Drug Administration has issued a Control Response Letter for the comp
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
11:39am, Monday, 14'th Aug 2023
Outlook Therapeutics (OTLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
08:45am, Tuesday, 01'st Aug 2023
ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevac
Outlook Therapeutics: August PDUFA May Be A Buy With Some Caveats
01:06am, Saturday, 10'th Jun 2023
OTLK is developing an ophthalmic formulation of bevacizumab. There is a logic behind this, and there's also positive data. However, certain developments stop me from being overly enthusiastic.
Why Shares of Outlook Therapeutics Rose Tuesday
01:59pm, Tuesday, 06'th Jun 2023
Outlook, a clinical-stage biotech, is awaiting potential approval for a wet AMD therapy. The therapy has a PDUFA date of Aug. 29 from the FDA.
Should You Buy Oncobiologics, Inc. (OTLK) After Golden Cross?
11:01am, Thursday, 25'th May 2023
From a technical perspective, Oncobiologics, Inc. (OTLK) is looking like an interesting pick, as it just reached a key level of support. OTLK's 50-day simple moving average crossed above its 200-day s
Outlook Therapeutics: August PDUFA For Wet AMD Blockbuster
05:58pm, Friday, 28'th Apr 2023
Oncobiologics, born in pursuit of oncology biosimilars, dramatically shifted its outlook, appropriately rechristening itself as Outlook Pharmaceuticals. Outlook has set its sights full bore on treatme
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
08:05am, Thursday, 27'th Apr 2023
Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in a live moderated fireside chat on Tuesday, May
Outlook Therapeutics ends 1Q with cash and equivalents of $52.3M; says it has sufficient capital into 4Q 2023
09:42am, Tuesday, 14'th Feb 2023
Outlook Therapeutics Inc (NASDAQ:OTLK) announced that it has ended its first quarter of fiscal 2023 with cash and equivalents of $52.3 million as of December 31, 2022, which the company says is expect
Outlook Therapeutics strengthens medical affairs and commercial expertise with new appointments
09:01am, Thursday, 19'th Jan 2023
Outlook Therapeutics Inc (NASDAQ:OTLK) has announced the appointments of Dr Surendra Sharma as senior vice president of medical affairs and Glen Olsheim as executive director of commercial excellence
Outlook Therapeutics plots course for wet AMD drug approval in year-end shareholder letter
12:06pm, Thursday, 29'th Dec 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) has announced financial results for its fiscal year ended September 30 and laid out plans for 2023 in an end-of-year letter. “Our fiscal year 2022 laid a solid
Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into securities purchase agreements with existing institutional and accredited investors for a registered direct offering priced at-the-marke
Outlook Therapeutics announces validation of marketing authorization application by EMA for ONS-5010 as treatment for wet AMD
09:01am, Thursday, 22'nd Dec 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) announced the validation of the company's Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for an investigational ophthalmic form
Outlook Therapeutics says FDA approval for Lytenava will make huge difference for those with vision loss
07:01am, Friday, 04'th Nov 2022
There's a question the CEO of Outlook Therapeutics Inc (NASDAQ:OTLK) likes to pose about why having US Food and Drug Administration (FDA)-approval will propel the company's upcoming treatment for reti
